Build status - In Progress

Evaluating the Safety and Tolerability of XmAb 18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)

Evaluating the Safety and Tolerability of XmAb 18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)
Recruiting
12 years - 99 years
All
Phase N/A
87 participants needed
1 Location

Brief description of study

The primary purposes of this research study is to determine the safety and tolerability of the investigational drug, XmAb18087, and if the XmAb18087 works in treating tumors like you have and side effects from XmAb18087, to find the best dose for treating your type of tumor. XmAb18087 is an investigational drug that is designed to activate your own cells to kill your tumor

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Neuroendocrine Tumors,Gastrointestinal Neoplasms,Digestive System Neoplasms,Neuroectodermal Tumors,Neoplasms,
  • Age: 12 years - 99 years
  • Gender: All

NET of pancreatic, gastrointestinal, lung, or undetermined origin Histologically confirmed GIST that is locally advanced or metastatic

Updated on 04 Aug 2024. Study ID: 832637

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center